AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11729008
Drug: One-person treatment
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-person treatment model (psychiatrist conducts psychotherapy and prescribes medication)
Trial: 9205763
Drug: ebrotidine (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ebrotidine (400 mg/day)
Trial: 9205763
Drug: ranitidine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ranitidine (300 mg/day in healing phase, 150 mg/day in follow-up phase)
Trial: 8427866
Drug: Vessel wall
RxNorm normalized name: acellular tissue engineered vessel Drug Implant [Symvess]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vessel wall shear stress calculated using a validated finite‐difference model of the Navier‐Stokes' equation with a coronary flow rate of 8 ml/sec.
Trial: 3629187
Drug: Aluminium-containing antacid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aluminium-containing antacid
Trial: 30348912
Drug: Traditional flushing
RxNorm normalized name: T8 Keto Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional flushing method with 10 ml syringe of saline
Trial: 16215308
Drug: Bicalutamide 50
RxNorm normalized name: bicalutamide 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bicalutamide 50 mg/day
Trial: 25015740
Drug: IORT as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IORT as APBI treatment
Trial: 25015740
Drug: IORT boost
RxNorm normalized name: BOOST
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IORT boost treatment
Trial: 18936479
Drug: Full-dose reirradiation
RxNorm normalized name: Rho(D) immune globulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-dose reirradiation combined with chemotherapy (RT arm)
Trial: 15932528
Drug: Topical 0.1%
RxNorm normalized name: adapalene topical 0.1% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.1% dexamethasone eye drops four times daily (group A)
Trial: 15932528
Drug: Topical 0.1%
RxNorm normalized name: adapalene topical 0.1% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.1% dexamethasone eye drops twice daily (group B)
Trial: 12598253
Drug: Remifentanil combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil combined with ketamine at 50 or 100 ng/mL
Trial: 12598253
Drug: Remifentanil at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil at 2 ng/mL
Trial: 1734901
Drug: Low-dose methotrexate
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose methotrexate (MTX) at a mean weekly dosage of 10.2 mg
Trial: 6524917
Drug: Moderate energy
RxNorm normalized name: Senergy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate energy supplement (0 g protein, 420 kcal)
Trial: 6524917
Drug: Protein supplement
RxNorm normalized name: PROTEIN SUPPLEMENT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein supplement (14 g protein, 84 kcal)
Trial: 21646823
Drug: Motivational Intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Motivational Intervention (MI) + Treatment as Usual (TAU)
Trial: 11989841
Drug: Octreotide 100
RxNorm normalized name: 1 ML octreotide 100 MCG/ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide 100 microg/h after an initial bolus of 100 microg plus terlipressin 2 mg
Trial: 10078672
Drug: Psychomotor test
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychomotor test 60 min after remifentanil infusion
Trial: 6834205
Drug: Related play
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Related play therapy
Trial: 6834205
Drug: Unrelated play
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unrelated play therapy
Trial: 6834205
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no preoperative preparation)
Trial: 29424008
Drug: 0.7 mg
RxNorm normalized name: naloxone 0.7 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.7 mg granisetron
Trial: 29424008
Drug: Granisetron groups
RxNorm normalized name: Granisetron
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Granisetron groups (1 mg and 0.7 mg)
Trial: 29934199
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural therapy plus standard care (10-14 sessions over 10 months)
Trial: 26655732
Drug: Low-dose cariprazine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cariprazine (1.5-4.5 mg/day)
Trial: 26655732
Drug: High-dose cariprazine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cariprazine (6-12 mg/day)
Trial: 24613434
Drug: Fermented milk
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fermented milk (FM) 80 mL/d
Trial: 24613434
Drug: Non-fermented milk
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-fermented milk (NFM) 80 mL/d
Trial: 20498097
Drug: Various treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various treatments for low libido in women (specific interventions not detailed)
Trial: 18799936
Drug: intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous immunoglobulin (IVIG, 1.0 g/kg/dose)
Trial: 15955958
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg of methylprednisolone (MP)
Trial: 15955958
Drug: 2,000 mg
RxNorm normalized name: garlic 2,000 mg ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2,000 mg of methylprednisolone (MP)
Trial: 12025911
Drug: Micronized purified
RxNorm normalized name: RAYON,PURIFIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronized purified flavonoid fraction (MPFF) - 450 mg of micronized diosmin and 50 mg of flavonoids expressed in hesperidin for 6 months
Trial: 8948610
Drug: Intralesional interferon-gamma
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional interferon-gamma (IFN-G) injections
Trial: 1721887
Drug: Isovolemic hemodilution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isovolemic hemodilution over 6 weeks with hydroxyethyl starch solutions (PCV down to 35-32%)
Trial: 1721887
Drug: Basic treatment
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic treatment of 75 mg of acetylsalicyclic acid daily
Trial: 6751656
Drug: 100-g oral
RxNorm normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100-g oral glucose load after 3-hour exercise
Trial: 27215976
Drug: Lurasidone adjunctive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lurasidone adjunctive therapy
Trial: 31377382
Drug: Robot-assisted gait
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robot-assisted gait training (G-EO System), 20 sessions of 45 minutes each.
Trial: 27567973
Drug: Child‐ and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Child‐ and Family‐Focused Cognitive-Behavioral Therapy (CFF‐CBT)
Trial: 17685676
Drug: Group 2
RxNorm normalized name: Chlamydophila psittaci biogroup 2 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 2 (medicine ball training)
Trial: 17685676
Drug: Group 1
RxNorm normalized name: Chlamydophila psittaci biogroup 1 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1 (control group with no medicine ball training)
Trial: 10535235
Drug: Al‐Anon facilitation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Al‐Anon facilitation therapy
Trial: 7768073
Drug: Tolcapone 200
RxNorm normalized name: tolcapone 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolcapone 200 mg and higher
Trial: 7768073
Drug: Tolcapone (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolcapone (5 to 800 mg)
Trial: 2382605
Drug: Urokinase (3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urokinase (3.0 million units over 30 minutes intravenously) with maximal antianginal therapy and intravenous heparin
Trial: 31896118
Drug: Intranasal insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal insulin (160 IU)
Trial: 24638884
Drug: Medication treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication treatment for ADHD
Trial: 24638884
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (behavior therapy and/or stimulant medication)
Trial: 21592234
Drug: Alfuzosin 10mg
RxNorm normalized name: Alfuzosin 10mg Oral tablet, extended release
DrugBank: Alfuzosin (DB00346)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alfuzosin 10mg daily for 4 weeks and dologesic (paracetamol+dextropropoxyphene, four tablets daily on demand) for 2 weeks
Trial: 19779491
Drug: 160 mg
RxNorm normalized name: nadolol 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160 mg valsartan (V group, n=22)
Trial: 19779491
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg valsartan plus low-dose trichlormethiazide (1 mg) (V+D group, n=21)
Trial: 10717350
Drug: DTP acellular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTP acellular vaccines
Trial: 10717350
Drug: DTP whole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTP whole cell vaccine
Trial: 10717350
Drug: 4-5 years
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-5 years after the third dose
Trial: 8741950
Drug: Methadone maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone maintenance (50 mg PO daily)
Trial: 8741950
Drug: Cocaine challenge
RxNorm normalized name: Cocaine
DrugBank: Cocaine (DB00907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine challenge doses (0, 12.5, 25, and 50 mg IV)
Trial: 3903789
Drug: Flupenthixol (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flupenthixol (0.5 to 2 mg a day)
Trial: 3903789
Drug: Diazepam (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (2.5 to 10 mg a day)
Trial: 3903789
Drug: Sulpiride (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulpiride (100 to 200 mg a day)
Trial: 30792342
Drug: Interdisciplinary model
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interdisciplinary model of care (smoking cessation support, home medicines review, home-based pulmonary rehabilitation)
Trial: 23918000
Drug: Electronic Urticaria
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electronic Urticaria Patient Daily Diary (eUPDD)
Trial: 23918000
Drug: Paper Urticaria
RxNorm normalized name: paper birch pollen extract
DrugBank: Betula papyrifera pollen (DB10831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paper Urticaria Patient Daily Diary (UPDD)
Trial: 21757939
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g paracetamol i.v.
Trial: 11343813
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg diclofenac sodium i.m.
Trial: 21757939
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg lornoxicam i.v.
Trial: 18835043
Drug: Aripiprazole (15‐30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole (15‐30 mg/day)
Trial: 18835043
Drug: Lithium (900‐1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium (900‐1500 mg/day)
Trial: 9513824
Drug: 2-week course
RxNorm normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2-week course of amoxicillin and tinidazole for index children and siblings younger than 18; 2-week course of Colloidal Bismuth Subcytrate and tinidazole for parents and siblings over 18
Trial: 7699213
Drug: LH‐RH analogs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LH‐RH analogs treatment for Group 1 patients (P.A.H. < -1 SDS) for 2 years
Trial: 7699213
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment for Group 2 patients (P.A.H. > -1 SDS) for 2 years
Trial: 2646988
Drug: Daily change
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily change of povidone-iodine dressing
Trial: 28199710
Drug: CBT‐I +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBT‐I + antidepressant (AD; escitalopram)
Trial: 28199710
Drug: CBT‐I +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBT‐I + placebo pill
Trial: 20406273
Drug: Home visits
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Home visits advising mothers about healthy feeding practices (monthly advice up to 6 months and then at 8, 10, and 12 months)
Trial: 15930443
Drug: Fortified dairy
RxNorm normalized name: Beano Dairy Defense
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fortified dairy product containing eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), oleic acid, folic acid, and vitamins A, B‐6, D, and E, 500 mL/d
Trial: 15930443
Drug: Semiskimmed milk
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semiskimmed milk with added vitamins A and D, 500 mL/d
Trial: 12885705
Drug: 18 g
RxNorm normalized name: flotufolastat F 18 gallium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18 g essential amino acids (EAA group)
Trial: 12885705
Drug: 40 g
RxNorm normalized name: PEG-40 GLYCERYL STEARATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 g balanced amino acids (BAA group)
Trial: 3693871
Drug: Temazepam (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temazepam (10 mg)
Trial: 9086127
Drug: New cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New cell culture-derived vaccinia virus vaccine administered intradermally
Trial: 9086127
Drug: New cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New cell culture-derived vaccinia virus vaccine administered intramuscularly
Trial: 9086127
Drug: Licensed vaccinia
RxNorm normalized name: vaccinia virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Licensed vaccinia vaccine administered by scarification
Trial: 7967338
Drug: Ticlopidine, 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticlopidine, 500 mg/day
Trial: 27049086
Drug: Wuzhi capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wuzhi capsule (one capsule in the morning and evening for 3 weeks)
Trial: 27049086
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no Wuzhi capsule)
Trial: 24906133
Drug: Intravenous propranolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous propranolol (1 mg)
Trial: 24906133
Drug: Oral propranolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral propranolol (40 mg)
Trial: 24906133
Drug: Correlation between
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Correlation between SBA concentration and propranolol oral AUC0-∞
Trial: 22969845
Drug: Vitamin B12
RxNorm normalized name: Vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin B12 + Goshajinkigan treatment (Group B)
Trial: 22969845
Drug: Vitamin B12
RxNorm normalized name: Vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin B12 treatment (Group A)
Trial: 15742266
Drug: Postoperative oral
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative oral antibiotic treatment
Trial: 15742266
Drug: Postoperative topical
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative topical antibiotic drops
Trial: 12093661
Drug: Mitomycin-C (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitomycin-C (0.05 mg/ml) applied topically to the filtering bleb on days 1, 2, and 3 after surgery (postoperative application)
Trial: 12093661
Drug: Mitomycin-C (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitomycin-C (0.2 mg/ml) applied by means of a sponge during surgery (intraoperative application)
Trial: 10503682
Drug: Nebulized budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nebulized budesonide (2 mg 8 hourly)
Trial: 10503682
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone (2 mg/kg at entry and again at 24 h)
Trial: 8879982
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of standardized ginseng extract Ginsana G 115
Trial: 29866165
Drug: High-flow nasal
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flow nasal cannula therapy (HFNC)
Trial: 27040801
Drug: 13 G
RxNorm normalized name: UREA 13 g TOPICAL TABLET [CLEAN-UP]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 13 G vacuum-assisted biopsy (VAB)
Trial: 27040801
Drug: 14 G
RxNorm normalized name: GINGER 14 g in 100 TOPICAL PATCH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14 G core needle biopsy (CNB)
Trial: 22541306
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as Usual (TAU-IS)
Trial: 22541306
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as Usual (TAU-OS)
Trial: 20930100
Drug: Cognitive behavior
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavior therapy (CBT) consisting of up to ten 1-hour sessions within 6 months
Trial: 17684525
Drug: Daily vitamin
RxNorm normalized name: Daily Vitamin Liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily vitamin D3 supplement plus 500 mg calcium (CaD group)
Trial: 17684525
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus 500 mg calcium (Ca group)
Trial: 12028741
Drug: Desipramine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desipramine (150 mg/day)
Trial: 1936066
Drug: Eterobarbital (DMMP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eterobarbital (DMMP) 400 mg
Trial: 1936066
Drug: Phenobarbital (PB)
RxNorm normalized name: Phenobarbital
DrugBank: Phenobarbital (DB01174)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenobarbital (PB) 200 mg
Trial: 7022286
Drug: VP-16-213 (etoposide)
RxNorm normalized name: etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: VP-16-213 (etoposide) administered orally at 150 mg/m2/day for 5 days every 3 weeks
Trial: 7022286
Drug: VP-16-213 (etoposide)
RxNorm normalized name: etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: VP-16-213 (etoposide) administered intravenously at 150 mg/m2 weekly
Trial: 30584047
Drug: Oral HIV
RxNorm normalized name: HIV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral HIV self-testing plus routine door-to-door HIV testing services
Trial: 30584047
Drug: Oral HIV
RxNorm normalized name: HIV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral HIV self-testing plus routine door-to-door HIV testing services (among men)
Trial: 26293044
Drug: Tac‐QD (tacrolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tac‐QD (tacrolimus once daily)
Trial: 15075539
Drug: 8-week treatment
RxNorm normalized name: Weeks and Leo Complete Lice Treatment KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8-week treatment interruption followed by a six to nine-drug rescue regimen
Trial: 15075539
Drug: Multidrug therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidrug therapy alone
Trial: 9483586
Drug: Lodoxamide 0.1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lodoxamide 0.1% ophthalmic solution (LOS)
Trial: 7831455
Drug: Haloperidol (neuroleptic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (neuroleptic treatment)
Trial: 3417462
Drug: Intermittent doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent doses of buprenorphine hydrochloride (0.3 mg intramuscularly every 3 to 6 hours)
Trial: 25222881
Drug: Indacaterol 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indacaterol 150 μg and Glycopyrronium 50 μg (combination)
Trial: 23886280
Drug: Personal Resilience
RxNorm normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Personal Resilience and Enrichment Programme (PREP), six weekly sessions focused on emotional awareness, expression and management, identifying roles and personal strengths, and effective problem-solving skills.
Trial: 20332355
Drug: Automated glucagon
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Automated glucagon plus insulin delivery
Trial: 3931467
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus insulin
Trial: 18836798
Drug: Chemoradiotherapy followed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chemoradiotherapy followed by chemotherapy
Trial: 12716689
Drug: Calcium supplements
RxNorm normalized name: CALCIUM SUPPLEMENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplements alone (1000 mg Ca/d)
Trial: 11028551
Drug: Perioperative enteral
RxNorm normalized name: lipase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative enteral immunonutrition (treatment group, n = 102)